Posted by Michael Wonder on 27 Mar 2024
Beyfortus approved in Japan for the prevention of RSV disease in infants
27 March 2024 - First and only RSV preventive option for broad infant population authorised for use in Japan.
AstraZeneca and Sanofi’s Beyfortus (nirsevimab), a long-acting monoclonal antibody, has been approved in Japan for the prophylaxis of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in all neonates, infants and children entering their first RSV season, and the prevention of RSV LRTD in neonates, infants and children at risk of serious RSV infection entering their first or second RSV season.
